Home » BioMerieux Spends $60M to Acquire Private Molecular Dx Firm

BioMerieux Spends $60M to Acquire Private Molecular Dx Firm

Sep 11, 2008
NEW YORK (GenomeWeb News) – BioMerieux today announced that is has acquired privately held molecular diagnostics firm AviaraDx for $60 million.
 
San Diego-based AviaraDx makes tests — the CancerTYPE ID and Breast Cancer IndexSM — that are used for the molecular classification of cancers and to aid oncologists in making therapeutic decisions. BioMerieux said that with the acquisition it gains validated cancer biomarkers as well as capabilities in gene expression profiling in tissues for oncology applications.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.